Literature DB >> 6352059

The mechanism of cell-mediated cytotoxicity. III. Protease-specific inhibitors preferentially block later events in cytotoxic T lymphocyte-mediated lysis than do inhibitors of methylation or thiol-reactive agents.

D Redelman, D Hudig.   

Abstract

Highly active mouse cytotoxic T lymphocytes (CTL) generated in secondary mixed-lymphocyte responses were used to examine the manner in which adenosine derivatives, thiol-specific reagents, or protease-specific probes affected CTL-mediated lysis (CML). The adenosine deaminase inhibitor deoxycoformycin (dCF) enhanced inhibition by adenosine (AR) or by deoxyadenosine (AdR), but not by 7-deazaadenosine (tubercidin). L-Homocysteinethiolactone (L-Hcy) acted synergistically with AR, but not with AdR or tubercidin, to block CML. Thus, AR derivatives may act both by affecting cellular methylation reactions, as demonstrated by the synergism between AR and L-Hcy, and by inhibiting other events required for CML. Conditions were then established to determine whether these reagents preferentially affected either the Ca2+-independent initial stage of cytolysis or the subsequent Ca2+-dependent events. Methylation inhibitors blocked lysis most effectively if added before effector-target binding. Similarly, the nonpenetrating thiol-specific reagent quaternary ammonium monobromobimane (qBBr) was more inhibitory when added prior to the Ca2+-dependent stage. Protease inhibitors such as alpha-1-antichymotrypsin and protease substrates such as acetyltyrosine ethyl ester (ATEE) or tyrosine ethyl ester (TEE) also inhibited CML. But, in contrast to qBBr or methylation inhibitors, neither TEE nor ATEE was more effective when added prior to the initial effector-target interaction. Furthermore, TEE did not appreciably affect CTL binding to target cells at concentrations that nearly abrogated CML. Thus, the implicated protease step is unique in that it does not appear to participate in recognition or binding.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352059     DOI: 10.1016/0008-8749(83)90206-x

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  Hydroxyl radical scavengers inhibit human lectin-dependent cellular cytotoxicity.

Authors:  M Melinn; H McLaughlin
Journal:  Immunology       Date:  1986-06       Impact factor: 7.397

2.  Immunohistochemical localization of granzyme B antigen in cytotoxic cells in human tissues.

Authors:  A Hameed; L D Truong; V Price; O Kruhenbuhl; J Tschopp
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

3.  Involvement of cell surface macromolecules sensitive to alkylating ketones in lysis by human peripheral blood NK cells.

Authors:  M M Dawson; U Shipton; M Moore
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

4.  Cytolytic effects of neutrophils: role for a membrane-bound neutral proteinase.

Authors:  S Pontremoli; E Melloni; M Michetti; O Sacco; B Sparatore; F Salamino; G Damiani; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Influence of acute-phase proteins on the activity of natural killer cells.

Authors:  Y Okumura; J Kudo; T Ikuta; S Kurokawa; H Ishibashi; H Okubo
Journal:  Inflammation       Date:  1985-06       Impact factor: 4.092

6.  Perforin is present only in normal activated Lyt2+ T lymphocytes and not in L3T4+ cells, but the serine protease granzyme A is made by both subsets.

Authors:  J A Garcia-Sanz; G Plaetinck; F Velotti; D Masson; J Tschopp; H R MacDonald; M Nabholz
Journal:  EMBO J       Date:  1987-04       Impact factor: 11.598

7.  Granules of cytolytic T-lymphocytes contain two serine esterases.

Authors:  D Masson; M Nabholz; C Estrade; J Tschopp
Journal:  EMBO J       Date:  1986-07       Impact factor: 11.598

8.  Purification and characterization of a T cell specific serine proteinase (TSP-1) from cloned cytolytic T lymphocytes.

Authors:  M M Simon; H Hoschützky; U Fruth; H G Simon; M D Kramer
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.